A Multicenter Phase II Study of AMG 337 in Patients with MET-Amplified Gastric/Gastroesophageal Junction/Esophageal Adenocarcinoma and Other MET-Amplified Solid Tumors.

Eric Van CutsemBoguslawa KaraszewskaYoon-Koo KangHyun Cheol ChungVeena ShankaranSalvatore SienaNing F GoHui YangMarco SchuppDavid Cunningham

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2018)

AMG 337 showed antitumor activity in MET-amplified G/GEJ/E adenocarcinoma but not in MET-amplified non-small-cell lung cancer.See related commentary by Ma, p. 2375.

Keyphrases

phase ii study
tyrosine kinase
locally advanced
squamous cell carcinoma
open label
rectal cancer
radiation therapy
double blind